Scandinavian Cardiovascular Journal

A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial

By Andre L. Lamy, Lars Rydén, Wesley Tong, On Behalf of the COMPASS Investigators

Computational studyInterventions

The paper

Andre L. Lamy, Lars Rydén, Wesley Tong, On Behalf of the COMPASS Investigators

Population Health Research Institute

Scandinavian Cardiovascular Journal, 6 Sep 2026